Table 1.

Summary of studies evaluating the effects of statin use in patients with NASH/NAFL.

Authors (Ref)	Study design	Statin	Population health status	Sample size	Main findings
Athyros et.al. (59)	Randomized trial (post-hoc analysis)	Atorvastatin vs. simvastatin	Patients with cardiovascular disease	437	-Participants treated with statins had improvement in liver tests (p < 0.0001) -Cardiovascular events occurred in 10% of patients with abnormal liver tests who received statin and 30% of patients with abnormal liver tests who did not receive statins (p < 0.0001)
Tikkanen et al. (60)	Randomized trial (post-hoc analysis)	Atorvastatin 80 mg/day vs. simvastatin 20–40mg/day	Coronary heart disease patients with normal and elevated baseline levels of serum alanine aminotransferase	1,081	Patients with elevated baseline aminotransferases, major cardiovascular event rates were 11.5% for simvastatin and 6.5% for atorvastatin, indicating a significant risk reduction with intensive statin therapy (HR, 0.556; 95% CI, 0.367–0.842; p = 0.0056)
Athyros et al. (40)	Randomized trial (post-hoc analysis)	Atorvastatin 30 mg/day vs. atorvastatin 20 mg/day.	Patients with metabolic syndrome without diabetes or cardiovascular disease	326	The number of events were none for the LDL-C <100 mg/dl group and 3 for the LDL-C <130 mg/dl group
NCT04679376 (active, not recruiting yet)	Randomized	Atorvastatin 40 mg/day vs. placebo	NASH patients	70	Primary objective: change in NASH score

HR, hazard-ratio; CI, confidence intervals.